Race Oncology Limited (RAONF)

USD 1.22

(0.0%)

Market Cap (In USD)

211.92 Million

Revenue (In USD)

4 Million

Net Income (In USD)

-13.81 Million

Avg. Volume

129.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.83-1.45
PE
-
EPS
-
Beta Value
1.821
ISIN
AU000000RAC3
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Daniel Tillett
Employee Count
-
Website
https://www.raceoncology.com
Ipo Date
2021-03-09
Details
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.